Revenue Recognition - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2019	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025	Dec. 31, 2024
Disaggregation of Revenue [Line Items]
Deferred revenue		$ 52,377	$ 38,230	$ 52,377	$ 38,230	$ 41,969	$ 36,592
Product revenues
Disaggregation of Revenue [Line Items]
Billing collection period (in months)				6 months
Extended billing collection period (in months)				3 months
Product revenues | Minimum
Disaggregation of Revenue [Line Items]
Approximate percentage of revenue collected within 6 months (as a percent)				85.00%
Product revenues | Maximum
Disaggregation of Revenue [Line Items]
Approximate percentage of revenue collected within 6 months (as a percent)				90.00%
Test Revenue
Disaggregation of Revenue [Line Items]
Increased revenue		$ 32,300	$ 55,100	$ 145,600	$ 134,700
Decrease in net loss per share ( in dollars per share)		$ 0.22	$ 0.40	$ 1.02	$ 0.99
BGI Genomics
Disaggregation of Revenue [Line Items]
Agreement term	10 years
Deferred revenue		$ 16,300		$ 16,300		$ 16,800
BGI Genomics | Oncology
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation							$ 20,000
Revenue recognized				$ 600	$ 400